Download PDF
Gesundheitsökonomie & Qualitätsmanagement 2021; 26(02): 88-92
DOI: 10.1055/a-1275-1636
Originalarbeit

Die wirtschaftliche Belastung durch ANCA-assoziierte Vaskulitiden in Deutschland – eine Versorgungsdatenstudie

The economic burden for ANCA-associated vasculitides in Germany – a claims data study
Bernhard Hellmich
1   Medius Klinik, Kirchheim/Teck
,
Philip Spearpoint
2   Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Schweiz
,
Angelika Deichmann
3   SKC Beratungsgesellschaft mbH, Hannover
,
Ina Buchholz
3   SKC Beratungsgesellschaft mbH, Hannover
,
Matthias P. Schönermark
3   SKC Beratungsgesellschaft mbH, Hannover
,
Peter Rutherford
2   Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Schweiz
,
Dieter Götte
2   Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Schweiz
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die wirtschaftliche Belastung durch ANCA-assoziierte Vaskulitiden (AAV), potenziell lebensbedrohliche Autoimmunerkrankungen, wurde mittels einer Versorgungsdatenanalyse untersucht.

In dieser retrospektiven Studie wurden anonymisierte, repräsentative Längsschnittdaten von gesetzlichen Krankenversicherungen bereitgestellt und Versorgungsaspekte von Patienten mit Granulomatose mit Polyangiitis (GPA) sowie mikroskopischer Polyangiitis (MPA) systematisch untersucht.

Eine hohe Hospitalisierungsrate und schwere begleitende Morbiditäten, insbesondere Nierenbeteiligungen, waren Haupttreiber für im Vergleich zur Allgemeinbevölkerung deutlich erhöhte Gesamtkosten für Patienten mit GPA oder MPA.

Die Versorgungsdatenanalyse bestätigt die hohen Kosten durch AAV für das deutsche Gesundheitssystem und beweist sich darüber hinaus als eine zuverlässige Methode.

Abstract

The economic burden caused by ANCA-associated vasculitides (AAV), potentially life-threatening autoimmune diseases, was investigated by means of a claims data analysis.

In this retrospective study, anonymized, representative longitudinal data were provided by German statutory health insurances and health care aspects of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) were systematically investigated.

A high hospitalization rate and severe concomitant morbidities, especially kidney involvement, were the main drivers of significantly increased overall costs for patients with GPA or MPA compared to the general population.

The claims data analysis confirms the high costs of AAV for the German health care system, and moreover proves to be a reliable method.

Schlüsselwörter

AAV - Vaskulitis - wirtschaftliche Belastung - Hospitalisierung - Kosten

Key words

AAV - vasculitis - economic burden - hospitalization - costs

Zusatzmaterial



Publication History

Article published online:
29 October 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11
    CrossrefPubMedGoogle Scholar
  • 2 Schirmer JH, Moosig F. S1 guidelines on diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol 2017; 76: 75-76
    CrossrefPubMedGoogle Scholar
  • 3 Robson J, Doll H, Suppiah R. et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2015; 54: 471-481
    CrossrefPubMedGoogle Scholar
  • 4 McGregor JG, Negrete-Lopez R, Poulton CJ. et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 2015; 30: 171-181
    CrossrefPubMedGoogle Scholar
  • 5 Raimundo K, Farr AM, Kim G. et al. Clinical and economic burden of anti-neutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol 2015; 42: 2383-2391
    CrossrefPubMedGoogle Scholar
  • 6 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R. et al. Effect of Wegener’s granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum 2002; 47: 320-325
    CrossrefPubMedGoogle Scholar
  • 7 Watts RA, Robson J, Pearce F. The global burden of anti-neutrophil cytoplasmic antibody vasculitis: high but unquantified. Rheumatology (Oxford) 2017; 56: 1439-1440
    PubMedGoogle Scholar
  • 8 Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) database. Pharmacoepidemiology and drug safety 2016; 25: 106-109
    CrossrefPubMedGoogle Scholar
  • 9 Hellmich B, Lamprecht P, Spearpoint P. et al. New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Under Revision, DOI:
    Google Scholar
  • 10 Statistisches Bundesamt Krankheitskostenrechnung 2015. In 2017
    Google Scholar
  • 11 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R. et al. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53: 93-99
    CrossrefPubMedGoogle Scholar
  • 12 Walsh M, Flossmann O, Berden A. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-548
    CrossrefPubMedGoogle Scholar
  • 13 Khan S, Amedia CA. Jr Economic burden of chronic kidney disease. J Eval Clin Pract 2008; 14: 422-434
    CrossrefPubMedGoogle Scholar
  • 14 Kong AM, Kim G, Michalska M. et al. Costs of disease relapses among individuals with granulomatosis with polyangiitis, or microscopic polyangiitis in the United States. Rheumatol Ther 2018; 5: 159-170
    CrossrefPubMedGoogle Scholar